SEC Form 4 · accession 0001013606-16-000197
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amanda L. DePalma
Officer — VP, Global Marketing
Period of report
Feb 4, 2016
Accepted (ET)
Feb 17, 2016 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 4, 2016 | A | 14,608 | $0.00 | A | 43,423 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to PurchaseF3 | $7.53 | Feb 4, 2016 | A | 46,377 | A | Mar 4, 2016 | Feb 4, 2026 | Option to Purchase | 46,377 | 46,377 | D |
Explanation of responses
- F1Time based restricted stock unit award.
- F2Balance includes 771 shares purchased through the Company's Employee Stock Purchase Plan as well as 3,000 shares purchased on the open market not previously reported due to being deemed immaterial.
- F3Options vest ratably over forty-eight months.